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Background: Little is known about the relationship between emotional distress and mortality in patients with
an implantable cardioverter deﬁbrillator (ICD). Our aim was to examine the predictive value of general neg-
ative and positive affect, and depressive symptoms (including its components somatic symptoms and
cognitive-affective symptoms) for mortality.
Methods: ICD patients (N=591, 81% male, mean age=62.7±10.1 years) completed the Global Mood Scale
to measure the independent dimensions negative and positive mood, and the Beck Depression Inventory
to measure depressive symptoms. Covariates consisted of demographic and clinical variables.
Results: During the median follow-up of 3.2 years, 96 (16.2%) patients died. After controlling for covariates,
negative affect was signiﬁcantly related to all-cause mortality (HR=1.034, p=0.002), whereas positive af-
fect was not (HR=1.007, p=0.61). Depressive symptoms were also independently associated with an in-
creased mortality risk (HR=1.031, p=0.030) and somatic symptoms of depression in particular
(HR=1.130, p=0.003), but cognitive-affective symptoms were not associated with mortality (HR=0.968,
p=0.29). When entering both signiﬁcant psychological predictors in a covariate-adjusted model, negative
mood remained signiﬁcant (HR=1.039, p=0.009), but somatic symptoms of depression did not
(HR=0.988, p=0.78). Similar results were found for cardiac-related death. Of covariates, increased age,
CRT, appropriate shocks were positively related to death.
Conclusions: Negative affect in general was related to mortality, but reduced positive affect was not. Depres-
sion, particularly its somatic symptoms, was also related to mortality, while cognitive-affective symptoms
were not. Future research may further focus on the differential predictive value of emotional distress factors,
as well as on mechanisms that relate emotional distress factors to mortality.
© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
The implantable cardioverter deﬁbrillator (ICD) constitutes the
main treatment of patients with ventricular arrhythmias. This treat-
ment has clear medical beneﬁts [1], but psychological problems
exist, with 25% to 33% of ICD patients experiencing anxiety or depres-
sive symptoms [2–4]. These emotions seem to emanate from the psy-
chological proﬁle of the patient [2] and to a lesser extent from ICD
shocks and advisories [5,6].
Little is known about the consequences of increased emotional
distress in ICD patients. An increased risk for life-threatening arrhyth-
mias has been found in patients with anxiety [7], depression [8], andsity, Department of Medical
g, The Netherlands. Tel.: +31
k).
nder the Elsevier OA license. clustering of chronic distress factors [9]. Emotional distress may also
increase the risk for mortality in ICD patients. Findings from clinical
trials suggest that poor quality of life is associated with mortality in
the ﬁrst year post-implantation [10]. In addition, mortality rates
may be higher in patients with a high level of ICD concerns [11], post-
traumatic stress symptoms [12], or a distressed personality (i.e., pa-
tients who inhibit the expression of negative emotions) [11].
Depressionmay also be related to mortality. Although one study did
not ﬁnd this relationship in ICD patients [13], depression has been relat-
ed tomortality in patientswith heart failure [14,15], and acute coronary
syndrome [16]. Depression has also been related tomortality in the gen-
eral population [17], as well as mortality in other patient populations,
such as patients with cancer [18] or diabetes [19,20]. A distinction has
to be made between somatic symptoms of depression (e.g., sleep difﬁ-
culties and fatigue) and cognitive-affective symptoms of depression
(e.g., shame, guilt, and a negative self-image). Both symptom dimen-
sions have been independently associatedwithmortality [21], although
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sociated with cognitive-affective symptoms of depression [22].
Besides negative mood states, positive mood states (e.g. feeling
active or cheerful) may also inﬂuence the mortality risk. Studies in
coronary patients have shown that reduced positive affect (that is,
anhedonia) is associated with an increased risk for major adverse car-
diac events andmortality [23,24]. Notably, positive affect is a different
dimension than negative affect and these relatively independent
mood states may differentially affect outcomes.
The objectives of the current study were to examine 1) the associ-
ation between positive and negative mood and mortality, and 2) the
association between depressive symptoms and mortality, with de-
pression also being subdivided into two symptom dimensions, i.e., so-
matic symptoms and cognitive-affective symptoms. Both all-cause
and cardiac-related deaths were included. We hypothesize that 1)
negative mood as well as reduced positive mood will be related to
mortality, and 2) depression, and particularly somatic symptoms of
depression, will be related to increased mortality.
2. Methods
2.1. Patient sample
Patients who underwent ICD implantation between May 2003 and February 2009
were included from two referral hospitals in the Netherlands (Amphia Hospital, Breda
and Catharina Hospital, Eindhoven). Inclusion criteria were implantation with an ICD
and age between 18 and 80 years. Exclusion criteria were signiﬁcant cognitive impair-
ments (e.g. dementia), life-threatening comorbidities (e.g. cancer), and insufﬁcient
knowledge of the Dutch language.
The study was approved by the Medical Ethics Committee of both participating
hospitals. The study was conducted in accordance with the Helsinki Declaration, and
all patients provided written informed consent.
The authors of this manuscript have certiﬁed that they comply with the Principles
of Ethical Publishing in the International Journal of Cardiology.
2.2. Psychological measures
Patients completed psychological measures at the time of implantation (between
1 day prior to implantation and 3 weeks after implantation), and at 2, 12 and
18 months follow-up.
2.2.1. Mood states
The Global Mood Scale (GMS) is a 20 item self-report questionnaire, with 10 items
measuring negative mood states (characterized by fatigue and malaise; e.g. feeling list-
less, wearied, helpless) and 10 items measuring positive mood states (characterized by
energy and sociability; e.g. feeling active, lively, enterprising) [25]. On a 5-point Likert
scale, ranging from 0 — not at all to 4 — extremely, patients rate to what extent they ex-
perienced each mood state lately. Total scores for each subscale range from 0 to 40. The
GMS is a reliable and valid measure of positive and negative mood states [25]. The GMS
was developed to measure emotional distress in cardiac patients, as an alternative to
traditional psychometric scales that may be burdensome to complete for cardiac pa-
tients who are not psychiatric patients and may not recognize themselves in the tradi-
tional psychometric scales, but do report feelings of fatigue [25]. These mood states
represent independent mood dimensions.
2.2.2. Depressive symptoms
The Beck Depression Inventory (BDI) is a 21-item self-report questionnaire that as-
sesses the presence and severity of depressive symptoms [26]. The BDI can be subdi-
vided in two subscales, with items 1–13 measuring cognitive-affective symptoms of
depression (e.g., feeling guilty, shame, pessimism, sense of failure) and items 14–21
measuring somatic symptoms of depression (e.g., sleep disturbance, fatigue, loss of ap-
petite, loss of libido) [26]. Each BDI item is rated on a Guttmann scale from 0 to 3, with
total BDI scores ranging from 0 to 63 and scores ≥10 indicating clinically relevant
levels of depressive symptoms [26]. The BDI is a reliable and valid measure of depres-
sive symptomatology and it is most frequently used in cardiac patients.
2.3. Demographic and clinical variables
Demographic variables included gender, age, and marital status (having a partner
vs. not having a partner) and were obtained via self-report. Clinical variables included
ICD indication (primary vs. secondary prevention), cardiac resynchronization therapy
(CRT; ICD vs. CRT-D), etiology (ischemic vs. non-ischemic cardiomyopathy), decreased
ejection fraction (LVEF ≤35% vs. N35%), diabetes, smoking, ACE inhibitors, and beta
blockers. These clinical variables were obtained from medical records at baseline, ex-
cept for smoking which was assessed via self-report.The occurrence of shocks was obtained from medical records, with electrophysiol-
ogists judging the appropriateness of ICD therapies on the basis of intracardiac electro-
grams. Only the most aggressive treatment per episode was counted, meaning that if a
patient experienced a ventricular arrhythmia for which ﬁrst ATPs were delivered and
then shocks, this episode was only counted as one shock.
These demographic and clinical variables were selected as covariates, because they
are related to mortality, are of importance in the ICD population, and have been used in
other studies that investigated the relationship between distress and mortality in car-
diac patients.
2.4. Mortality
Medical records were checked to see when the patient had last visited the hospital
or when a patient had died. If information from the hospital was inaccurate or when a
patient had died, the treating cardiologist or general practitioner was consulted for
mortality status and cause of mortality. Both all-cause and cardiac-related mortalities
were included as endpoints.
2.5. Statistical analyses
The frequency distribution of each variable is ﬁrst examined for missing data. Cases
with missing values on most of the baseline measurements of GMS items, BDI items
and clinical variables are excluded from the analysis. If a case has a missing value on
follow-up measurements for GMS and BDI, this missing value was imputed with the
average of existing scores. In total, 21 patients had no score at the 2-month
time-point, 38 patients at 12-months and 66 patients at 18-months follow-up.
Baseline characteristics of the patients with respect to the mortality status of the
patients at the end of the study are examined. The Chi-square test is used to compare
binary categories while a t-test for independent samples is used to compare the aver-
ages of alive and dead patients on baseline continuous variables.
We ﬁt a series of Cox regression models using the baseline measurements to deter-
mine the univariable effect of each variable on mortality over time. Next, multivariable
Cox regression models are ﬁtted, including GMS Negative Mood and GMS Positive
Mood in the ﬁrst model, the BDI total score in the second model, and BDI Somatic
Symptoms and BDI Cognitive-Affective Symptoms in the third model. The ﬁrst series
of analyses include baseline measurements of GMS and BDI scales and the secondary
series of analyses include the follow-up measurements on GMS and BDI scales as
time dependent variables. In determining the independent effects of GMS and BDI
scales on mortality, we decided a priori to control for the demographic variables age,
gender and relationship, and the clinical variables indication, CAD, CRT, LVEF, diabetes,
smoking, beta-blockers, ACE inhibitors, appropriate shocks, and inappropriate shocks.
Finally, if two or more GMS or BDI subscales were signiﬁcantly related to mortality,
these were entered in one covariate-adjusted model to determine their independent
predictive value for mortality. The hazard ratio (HR) and 95% conﬁdence intervals for
the HR are reported. To illustrate the results using plots of survival functions, categor-
ical variables were constructed for the psychological variables that were signiﬁcantly
related to mortality. The categories were made with the median score at baseline as
cut-off, with patients with a score below or equal to the median value being classiﬁed
to the low group and those patients with scores greater than the median value being
classiﬁed in the high group. All analyses were performed for all-cause mortality and
cardiac-related mortality.
All tests are two sided and a p-value below 0.05 indicates a statistically signiﬁcant
effect. All analyses were performed using SPSS.17 for Windows.
3. Results
3.1. Patient characteristics and mortality
Among 645 patients whose data on demographic and clinical vari-
ables are obtained at baseline as well as GMS and BDI assessments at
follow-up, 591 (91.6%) are included in the analysis. Patients who
were not included in the analysis had missing data on the baseline
measurements, on GMS and/or BDI items and/or on clinical variables.
Included patients differed from patients who were not included on
age (62.6±10.1 years vs. 66.8±9.6 years, t=3.0, df=643,
p=.003), marital status (not having a partner: 26.8% vs. 13.2%,
chi-square=7.6, df=1, p=.006), and ICD indication (secondary pre-
vention: 52.8% vs. 35.7%, chi-square=6.1, df=1, p=.013). No differ-
ences were found on other baseline variables.
The median follow-up period is 1150 days (range 281 to
2384 days) or about 3.2 years (range 0.8 to 6.5 years). By the end of
the study period (at least January 1, 2009), 16.2% (n=96) of the pa-
tients had died from all-causes and 11.7% (n=69) had died from
cardiac-related causes. Table 1 shows demographic, clinical, and psy-
chological characteristics of both the total sample (n=591) and
Table 1
Summary of patient characteristics by all-cause mortality.
Characteristics N (%) Mortality (%) p
Total 591 16.2
Gender
Male 477 (80.7) 17.0 0.320
Female 114 (19.3) 13.2
Relationship
Yes 511 (86.5) 16.2 0.999
No 80 (13.5) 16.3
Smoker
No 486 (82.2) 16.3 0.987
Yes 105 (17.8) 16.2
CRT
No 412 (69.7) 12.6 b0.001
Yes 179 (30.3) 24.6
Diabetes
No 483 (81.7) 14.9 0.062
Yes 108 (18.3) 22.2
LVEF
N35% 102 (17.3) 8.8 0.026
≤35% 489 (82.7) 17.8
Indication
Primary 380 (64.3) 16.3 0.949
Secondary 211 (35.7) 16.1
CAD
No 161 (27.2) 11.8 0.073
Yes 430 (72.8) 17.9
Beta-blockers
No 106 (17.9) 22.6 0.049
Yes 485 (82.1) 14.8
ACE-inhibitors
No 191 (32.3) 17.8 0.478
Yes 400 (67.7) 15.5
Appropriate shock (18 months)
No 528 (89.3) 15.0 0.014
Yes 63 (10.7) 27.0
Inappropriate shock (18 months)
No 561 (94.9) 16.2 0.949
Yes 30 (5.1) 16.7
Combined
Mean±SD
Dead
Mean±SD
Alive
Mean±SD
p-value
Age (years) 62.7±10.1 66.6±8.5 61.9±10.3 b0.001
GMS Negative Mood 14.2±10.4 18.1±10.7 13.4±10.2 b0.001
GMS Positive Mood 19.6±9.0 18.3±9.1 19.8±8.9 0.111
BDI total score 8.7±6.7 10.6±6.9 8.3±6.5 0.002
BDI Cognitive-Affective
Symptoms
3.6±4.2 4.1±4.3 3.5±4.2 0.245
BDI Somatic Symptoms 4.6±3.1 6.0±3.3 4.4±3.0 b0.001
CAD = coronary artery disease; CRT = cardiac resynchronization therapy; LVEF = left
ventricular ejection fraction; N = number; SD = standard deviation.
Signiﬁcant p-values are highlighted in bold face.
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on p-values, age, CRT, LVEF, beta-blockers, appropriate shocks, GMS
Negative Mood, BDI total score, and BDI Somatic Symptoms were sig-
niﬁcantly associated with all-cause mortality status. Similar results
were found for cardiac-related mortality, although only a trend was
found for LVEF (p=0.096) and non-signiﬁcance was found for appro-
priate shocks (p=0.130). These comparisons do not take time until
death into account, nor do they control for the effect of the other
variables.
3.2. Univariable predictors of all-cause and cardiac-related mortality
Univariable Cox regression analyses showed that GMS Negative
Mood was statistically signiﬁcant related to mortality rate (all-cause
death: HR=1.040, 95% CI=1.020–1.059, pb0.001; cardiac-related
death: HR=1.053, 95% CI=1.029–1.077, pb0.001), with patients
with higher negative mood dying sooner, while GMS Positive Mood
was not (all-cause death: HR=0.984, 95% CI=0.962–1.006,p=1.153; cardiac-related death: HR=0.981, 95% CI=0.956–1.007,
p=0.156). BDI Cognitive-Affective symptoms were also not signiﬁ-
cantly related to mortality rate (all-cause death: HR=1.024, 95%
CI=0.980–1.069, p=0.290; cardiac-related death: HR=1.024, 95%
CI=0.973–1.076, p=0.354), while the BDI total score (all-cause
death: HR=1.040, 95% CI=1.014–1.067, p=0.003; cardiac-related
death: HR=1.049, 95% CI=1.019–1.080, p=0.001) and BDI Somatic
Symptoms (all-cause death: HR=1.136, 95% CI=1.074–1.200,
pb0.001; cardiac-related mortality: HR=1.176, 95% CI=1.105–
1.251, pb0.001) were related to mortality, with higher BDI scores
entailing a higher mortality risk.
Age (all-cause death: HR=1.057, 95% CI=1.032–1.083, pb0.001;
cardiac-related death: HR=1.054, 95% CI=1.025–1.084, pb0.001),
CRT (all-cause death: HR=1.994, 95% CI=1.334–2.980, p=0.001;
cardiac-related death: HR=2.421, 95% CI=1.509–3.884, pb0.001),
LVEF (all-cause death: HR=2.417, 95% CI=1.215–4.805, p=0.012;
cardiac-related death: HR=2.200, 95% CI=1.006–4.813, p=0.048),
diabetes (all-cause death: HR=1.682, 95% CI=1.059–2.672,
p=0.028), and use of beta blocker (cardiac-related death:
HR=0.563, 95% CI=1.332–0.955, p=0.033) appear to be related to
mortality rate among the demographic and clinical variables. Appro-
priate shocks (all-cause death: HR=1.637, 95% CI=0.968–2.767,
p=0.066; cardiac-related death: HR=1.456, 95% CI=0.764–2.778,
p=0.254) were marginally related to mortality and inappropriate
shocks (all-cause death: HR=1.092, 95% CI=0.443–2.689,
p=0.848; cardiac-related death: HR=1.546, 95% CI=0.622–3.847,
p=0.349) were not related to mortality.3.3. Multivariable predictors of all-cause mortality
The ﬁrst multivariable model indicated that the GMS Negative
Mood was still signiﬁcantly related to mortality (Table 2), with a
1 unit increase in the baseline GMS Negative Mood score increasing
the hazard rate by 3.4%, keeping other variables constant. Baseline
GMS Positive Mood was not related to mortality. The second multi-
variate model showed that the baseline BDI total score was signiﬁ-
cantly related to the rate of mortality (HR=1.031, 95% CI=1.003–
1.059, p=0.030) (table not shown). The third model showed that
baseline BDI Somatic Symptoms were still signiﬁcantly related to
mortality (Table 2), with a 1 unit raise in score increasing the mortal-
ity rate by 13.0% keeping the other variables in the model constant.
BDI Cognitive-Affective symptoms were not predictive. The ﬁnal mul-
tivariable model with GMS Negative Mood and BDI Somatic Symp-
toms showed that GMS Negative Mood remained signiﬁcant
(HR=1.039, 95% CI=1.010–1.068, p=0.009) but BDI Somatic
Symptoms did not (HR=0.988, 95% CI=0.911–1.073, p=0.78)
(table not shown). These latter results should be interpreted with
caution given the high correlation between GMS Negative Mood
and BDI Somatic Symptoms (r=0.69).
Secondary analyses showed similar results, with a signiﬁcant in-
creased risk for the time-varying covariates of GMS Negative Affect
(HR=1.047, 95% CI=1.024–1.069, pb0.001), BDI total score
(HR=1.038, 95% CI=1.012–1.065, p=0.004), and BDI Somatic
Symptoms (HR=1.150, 95% CI=1.069–1.237, pb0.001), indicating
that a 1 unit increase in for instance GMS Negative Affect at any of
the follow-up time points is associated with a 4.7% increase in mortal-
ity risk.
Older age, CRT, and appropriate shocks were signiﬁcantly related
to mortality rate in multivariable baseline and follow-up Cox models
among the demographic and clinical variables.
Fig. 1 shows the plots of survival functions, with separate curves for
low and high groups of GMSNegativeMood and BDI Somatic Symptoms
after keeping demographic and clinical variables constant. The differ-
ence is large and clearly visible for both variables, with death occurring
sooner in patients with high scores on these variables.
Table 2
Multivariable Cox regression models for all-cause death.
GMS scales BDI scales
HR 95% CI p HR 95% CI p
Centered age (years) 1.053 1.025,
1.081
b0.001 1.046 1.018,
1.074
b0.001
Gender (female) 0.804 0.451,
1.430
0.457 0.770 0.434,
1.366
0.371
Relationship (yes) 0.850 0.460,
1.571
0.605 0.902 0.488,
1.667
0.742
Secondary prevention 0.874 0.533,
1.432
0.593 0.859 0.524,
1.409
0.548
CAD 1.278 0.736,
2.217
0.383 1.347 0.777,
2.333
0.288
CRT 1.571 0.995,
2.479
0.052 1.582 1.071,
2.541
0.024
LVEF≤35% 1.402 0.637,
3.086
0.402 1.421 0.648,
3.117
0.381
Diabetes 1.349 0.826,
2.204
0.232 1.398 0.861,
2.271
0.175
Smoker 1.136 0.657,
1.964
0.647 1.091 0.632,
1.885
0.754
Beta-blockers 0.644 0.402,
1.033
0.068 0.712 0.439,
1.155
0.169
ACE-inhibitors 0.770 0.502,
1.182
0.232 0.760 0.496,
1.164
0.207
Appropriate shocks 2.304 1.308,
4.060
0.004 2.206 1.248,
3.599
0.006
Inappropriate shocks 0.921 0.369,
2.300
0.860 0.872 0.350,
2.173
0.769
GMS negative mooda 1.034 1.012,
1.056
0.002
GMS positive mooda 1.007 0.981,
1.033
0.605
BDI Somatic
Symptomsa
1.130 1.042,
1.226
0.003
BDI Cognitive-affective
Symptomsa
0.968 0.910,
1.028
0.289
CAD = coronary artery disease; CI = conﬁdence interval; CRT = cardiac
resynchronization therapy; HR = Hazard ratio; LVEF = left ventricular ejection
fraction.
a Baseline measurement.
A
Number at risk
Low 315 256 117 46
High 276 218 99 43
B
Number at risk
Low 329 273 132 56
High 262 201 84 33
HR=1.70, 95%CI=1.059-2.730, p=0.028
HR=1.81, 95%CI=1.126-2.894, p=0.014
Fig. 1. Curves of survival probability over time for GMS Negative Mood [A] and BDI So-
matic Symptoms [B] in multivariable models.
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Table 3 shows that similar results were found for cardiac-related
mortality, with a 1 unit increase being associated with a 4.0% in-
creased risk of mortality for baseline GMS Negative Affect, a 3.9% in-
creased risk for baseline BDI total score (data not shown) and a
21.3% increased risk for BDI Somatic Symptoms. Also, independent
predictive risks were found for follow-up GMS Negative Affect
(HR=1.054, 95% CI=1.028–1.081, pb0.001), BDI total score
(HR=1.047, 95% CI=1.017–1.078, p=0.002), and BDI Somatic
Symptoms (HR=1.191, 95% CI=1.096–1.294, pb0.001).
4. Discussion
The ﬁndings of this prospective study indicate that emotional dis-
tress is related to all-cause as well as cardiac-related mortalities in pa-
tients with an ICD. Particularly general negative mood and somatic
symptoms of depression predicted mortality.
Positive mood as measured by the GMS was not related to mortal-
ity. This corroborates results from at least one study in coronary pa-
tients that also used the GMS and demonstrated that changes in
positive mood were unrelated to mortality [27], but it is in contrast
to other studies that demonstrated a higher mortality risk in cardiac
patients with reduced positive mood [23,24]. We can only speculate
why we found no association. The actual effect of reduced positive
mood for mortality may be small and our sample may have been
too small to detect this effect. It is also possible that the GMS and
the Hospital Anxiety and Depression Scale, which was used in oneof the positive studies, are fundamentally different measures of posi-
tive mood.
Previous studies have shown that psychological factors, such as
ICD concerns [11], the distressed personality [11], and impaired qual-
ity of life [10] are associated with mortality in ICD patients. We ex-
tend the literature in ICD patients with the current ﬁndings that
general negative mood is also associated with mortality. A total
score of depression has been related to mortality in other cardiac
populations [14,16], but not in the ICD population [13] or in cancer
population [18,28]. The depression-associated risk of mortality may
be more driven by somatic symptoms of depression, rather than cog-
nitive affective symptoms of depression [22], which we were able to
conﬁrm in this cohort of ICD patients. The mortality risk associated
with somatic symptoms may only be partially attributable to markers
of disease status, as the risk was independent of ICD indication, CRT,
CAD, LVEF and occurrence of shocks, and thus independent of disease
severity, which was also found in previous studies [22].
Several behavioral and clinical factors may serve as mechanisms in
the relationship between negative mood and mortality. Results
among cardiac patients suggest that patients who were depressed
Table 3
Multivariable Cox regression models for cardiac-related death.
GMS scales BDI scales
HR 95% CI p HR 95% CI p
Centered age (years) 1.048 1.017,
1.081
0.002 1.038 1.006,
1.070
0.018
Gender (Female) 0.869 0.452,
1.670
0.673 0.796 0.415,
1.528
0.492
Relationship (yes) 0.908 0.450,
1.833
0.789 1.024 0.509,
2.062
0.946
Secondary prevention 1.015 0.565,
1.822
0.961 1.003 0.556,
1.811
0.992
CAD 1.148 0.616,
2.139
0.663 1.247 0.669,
2.327
0.487
CRT 1.857 1.081,
3.189
0.025 2.007 1.172,
3.436
0.011
LVEF≤35% 1.225 0.495,
3.033
0.660 1.192 0.481,
2.951
0.705
Diabetes 1.157 0.638,
2.099
0.631 1.176 0.650,
2.127
0.592
Smoker 1.212 0.643,
2.285
0.553 1.176 0.624,
2.216
0.615
Beta-blockers 0.570 0.332,
0.981
0.043 0.651 0.373,
1.135
0.130
ACE-inhibitors 0.854 0.512,
1.424
0.544 0.841 0.505,
1.403
0.508
Appropriate shocks 1.976 0.989,
3.948
0.054 1.826 0.910,
3.665
0.090
Inappropriate shocks 1.410 0.556,
3.576
0.469 1.261 0.499,
3.192
0.624
GMS Negative Mooda 1.049 1.023,
1.076
b0.001
GMS Positive Mooda 1.013 0.983,
1.044
0.413
BDI Somatic
Symptomsa
1.213 1.106,
1.330
b0.001
BDI Cognitive-affective
Symptomsa
0.932 0.867,
1.003
0.059
CAD = coronary artery disease; CI = conﬁdence interval; CRT = cardiac
resynchronization therapy; HR = Hazard ratio; LVEF = left ventricular ejection
fraction.
a Baseline measurement.
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[14]. Patients with mood disorders may have more comorbidities
than patients without mood disorders [14]. In addition, disturbed au-
tonomic balance, indicated by low heart rate variability, may be an
important mediator in the relationship between depression and mor-
tality in cardiac patients [30,31], including ICD patients [32]. Speciﬁ-
cally somatic symptoms of depression have been related to lower
heart rate variability in patients with stable coronary heart disease,
while cognitive depressive symptoms were not [33]. This ﬁnding
could explain why only somatic symptoms of depression are related
to mortality. Finally, the relationship between negative emotions
and mortality may be explained by the increased risk of arrhythmias
and ICD shocks in patients with chronic levels of negative emotions
[9] and depression [8]. Shocks were related to mortality in the current
study, as well as in previous studies [34]. The increased arrhythmia
risk in these distressed patients may again be related to disturbed au-
tonomic balance.
A number of limitations must be acknowledged. First, we did not
have information on physical activity and medication adherence,
which are shown to be related to depressive mood [14,29]. Second,
depression was assessed with a self report questionnaire where a di-
agnostic interview may perform better in classifying patients as de-
pressed. Third, information on heart failure symptomatology (i.e.,
NYHA class) was incomplete and therefore not included in analyses.
However, other variables that are related to heart failure severity
were included, such as ejection fraction, CRT, and presence of CAD.
Of note, CRT, but not EF, was an independent predictor of mortality.
Presumably, this is the result of the strong interrelatedness betweenEF and CRT, with 35.5% of patients with CRT having a low EF com-
pared to 2.0% of patients without CRT (pb .001). Fourth, patients
that were included in the study were slightly younger and more
oftenmarried andmore often had received the ICD for secondary pur-
poses. However, the impact of these differences on the results is un-
known, but may have been small. The strengths of this prospective
study include its relatively long follow-up period, the large sample
size, and the validated assessment of psychological variables.
Future studies are warranted to further study the relationship be-
tween psychological factors and mortality in ICD patients, as this
study is only one of the few studies investigating this topic. Future
studies should examine the impact of a clinical diagnosis of depres-
sion as assessed with a structured interview. In addition, research
should focus on behavioral and clinical mechanisms that may explain
this relationship. When research is directed at the impact of depres-
sion, it seems important to differentiate somatic symptoms of depres-
sion from cognitive-affective symptoms of depression. Finally, future
research may examine whether the impact of emotional distress on
mortality is age-dependent.
Awareness and timely identiﬁcation of ICD patients with general
negative mood states and speciﬁcally somatic symptoms of depres-
sion seems warranted, as depressed patients have an increased risk
for mortality, which has been shown in several studies in other cardi-
ac and non-cardiac patients, and for new life-threatening arrhyth-
mias. Patients may be screened for depression with the BDI and for
negative mood with the GMS, which are short self-report question-
naires that can easily be interpreted by the health care profession,
such as an ICD nurse. Unfortunately, results from large intervention
trials in cardiac patients have shown mixed ﬁndings. The majority
of studies failed to show an improvement of cardiovascular outcomes
after treatment of depression [35,36], which may have been caused
by a substantial group of patients at increased risk for mortality
who did not respond to the depression intervention [37]. Similarly,
studies in ICD patients have not yet demonstrated a beneﬁcial effect
of psychological interventions on prevention of shocks and mortality
[38,39]. Results from comparable studies in other patient populations
are sparse, but point in the same direction [40,41]. Nevertheless an
argument has been made that depression is a burden on its own
and as such cardiac patients should screened and treated for depres-
sion [35,36].
Relationship with industry
There are no relationships with industry that need to be disclosed
for Drs. Habibovic and Prof. Dr. Denollet. Dr. Van den Broek has re-
ceived speaker's fee from the Sorin Group. Dr. Alings has received
consultation and speakers fees from Bayer, Boehringer Ingelheim,
MSD, and Sanoﬁaventis. In addition, Dr. Alings reports that the De-
partment of Clinical Electrophysiology of the Amphia Hospital has re-
ceived unrestricted educational grants from Boston Scientiﬁc
Nederland, Medtronic Nederland, and St. Jude Medical Nederland.
Dr. Van der Voort has received speaker's fee from Medtronic.
Funding
This study was supported by the Netherlands Organization for
Scientiﬁc Research, The Hague, The Netherlands with a VICI grant
(453-04-004) to Prof. Dr. Johan Denollet.
Acknowledgments
We would like to thank Eefje Postelmans and Hidde Weetink for
inclusion of the patients into the study.
The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing in the International Journal
of Cardiology.
332 K.C. van den Broek et al. / International Journal of Cardiology 165 (2013) 327–332References
[1] Epstein AE. Beneﬁts of the implantable cardioverter-deﬁbrillator. J Am Coll Cardiol
2008;52:1122–7.
[2] Pedersen SS, Spindler H, Johansen JB, Mortensen PT. Clustering of poor device ac-
ceptance and type D personality is associated with increased distress in Danish
cardioverter-deﬁbrillator patients. Pacing Clin Electrophysiol 2009;32:29–36.
[3] Bilge AK, Ozben B, Demircan S, Cinar M, Yilmaz E, Adalet K. Depression and anxi-
ety status of patients with implantable cardioverter deﬁbrillator and precipitating
factors. Pacing Clin Electrophysiol 2006;29:619–26.
[4] Van den Broek KC, Nyklicek I, Van der Voort PH, Alings M, Denollet J. Shocks, per-
sonality, and anxiety in patients with an implantable deﬁbrillator. Pacing Clin
Electrophysiol 2008;31:850–7.
[5] Pedersen SS, van den Berg M, Theuns DA. A viewpoint on the impact of device ad-
visories on patient-centered outcomes. Pacing Clin Electrophysiol 2009;32:
1006–11.
[6] Pedersen SS, Van Den Broek KC, Van Den Berg M, Theuns DA. Shock as a determi-
nant of poor patient-centered outcomes in implantable cardioverter deﬁbrillator
patients: is there more to it than meets the eye? Pacing Clin Electrophysiol
2010;33:1430–6.
[7] Dunbar SB, Kimble LP, Jenkins LS, et al. Association of mood disturbance and ar-
rhythmia events in patients after cardioverter deﬁbrillator implantation. Depress
Anxiety 1999;9:163–8.
[8] Whang W, Albert CM, Sears Jr SF, et al. Depression as a predictor for appropriate
shocks among patients with implantable cardioverter-deﬁbrillators: results from
the Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol
2005;45:1090–5.
[9] van den Broek KC, Nyklicek I, van der Voort PH, Alings M, Meijer A, Denollet J. Risk
of ventricular arrhythmia after implantable deﬁbrillator treatment in anxious
type D patients. J Am Coll Cardiol 2009;54:531–7.
[10] Kao CW, Friedmann E, Thomas SA. Quality of life predicts one-year survival in pa-
tients with implantable cardioverter deﬁbrillators. Qual Life Res 2010;19:307–15.
[11] Pedersen SS, van den Broek KC, Erdman RA, Jordaens L, Theuns DA. Pre-implanta-
tion implantable cardioverter deﬁbrillator concerns and type D personality in-
crease the risk of mortality in patients with an implantable cardioverter
deﬁbrillator. Europace 2010;12:1446–52.
[12] Ladwig KH, Baumert J, Marten-Mittag B, Kolb C, Zrenner B, Schmitt C. Posttrau-
matic stress symptoms and predicted mortality in patients with implantable
cardioverter-deﬁbrillators: results from the prospective living with an implanted
cardioverter-deﬁbrillator study. Arch Gen Psychiatry 2008;65:1324–30.
[13] Tzeis S, Kolb C, Baumert J, et al. Effect of depression on mortality in implantable
cardioverter deﬁbrillator recipients — ﬁndings from the prospective LICAD
study. Pacing Clin Electrophysiol 2011;34:991–7.
[14] Zuluaga MC, Guallar-Castillon P, Rodriguez-Pascual C, Conde-Herrera M, Conthe P,
Rodriguez-Artalejo F. Mechanisms of the association between depressive symp-
toms and long-term mortality in heart failure. Am Heart J 2010;159:231–7.
[15] van den Broek KC, Deﬁlippi CR, Christenson RH, Seliger SL, Gottdiener JS, Kop WJ.
Predictive value of depressive symptoms and B-type natriuretic peptide for
new-onset heart failure and mortality. Am J Cardiol 2011;107:723–9.
[16] van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression
following myocardial infarction with mortality and cardiovascular events: a
meta-analysis. Psychosom Med 2004;66:814–22.
[17] Schulz R, Beach SR, Ives DG, Martire LM, Ariyo AA, Kop WJ. Association between
depression and mortality in older adults: the Cardiovascular Health Study. Arch
Intern Med 2000;160:1761–8.
[18] Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis.
Psychol Med 2010;40:1797–810.
[19] Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse
health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care
2003;26:2822–8.[20] Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease
mortality among adults with andwithout diabetes. Diabetes Care 2005;28:1339–45.
[21] Frasure-Smith N, Lesperance F. Depression and other psychological risks follow-
ing myocardial infarction. Arch Gen Psychiatry 2003;60:627–36.
[22] Martens EJ, Hoen PW, Mittelhaeuser M, de Jonge P, Denollet J. Symptom dimen-
sions of post-myocardial infarction depression, disease severity and cardiac prog-
nosis. Psychol Med 2010;40:807–14.
[23] Denollet J, Pedersen SS, Daemen J, de Jaegere P, Serruys PW, van Domburg RT. Re-
duced positive affect (anhedonia) predicts major clinical events following im-
plantation of coronary-artery stents. J Intern Med 2008;263:203–11.
[24] Davidson KW, Burg MM, Kronish IM, et al. Association of anhedonia with recur-
rent major adverse cardiac events and mortality 1 year after acute coronary syn-
drome. Arch Gen Psychiatry 2010;67:480–8.
[25] Denollet J. Emotional distress and fatigue in coronary heart disease: the Global
Mood Scale (GMS). Psychol Med 1993;23:111–21.
[26] Beck AT, Steer RA. Manual for the revised Beck Depression Inventory; 1993.
[27] Denollet J, Brutsaert DL. Reducing emotional distress improves prognosis in coro-
nary heart disease: 9-year mortality in a clinical trial of rehabilitation. Circulation
2001;104:2018–23.
[28] Chang G, Orav EJ, Tong MY, Antin JH. Predictors of 1-year survival assessed at the
time of bone marrow transplantation. Psychosomatics 2004;45:378–85.
[29] Ziegelstein RC, Howard B. Depression and poor adherence to lipid-lowering med-
ications among patients with coronary artery disease. J Psychosom Res 2010;69:
175–7.
[30] Stein PK, Domitrovich PP, Huikuri HV, Kleiger RE. Traditional and nonlinear heart
rate variability are each independently associated with mortality after myocardial
infarction. J Cardiovasc Electrophysiol 2005;16:13–20.
[31] Carney RM, Blumenthal JA, Freedland KE, et al. Low heart rate variability and the
effect of depression on post-myocardial infarction mortality. Arch Intern Med
2005;165:1486–91.
[32] Francis JL, Weinstein AA, Krantz DS, et al. Association between symptoms of de-
pression and anxiety with heart rate variability in patients with implantable car-
dioverter deﬁbrillators. Psychosom Med 2009;71:821–7.
[33] de Jonge P, Mangano D, Whooley MA. Differential association of cognitive and so-
matic depressive symptoms with heart rate variability in patients with stable cor-
onary heart disease: ﬁndings from the Heart and Soul Study. Psychosom Med
2007;69:735–9.
[34] Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable
cardioverter-deﬁbrillator therapy for the prevention of sudden cardiac death. J
Am Coll Cardiol 2008;52:1111–21.
[35] Whooley MA. To screen or not to screen? Depression in patients with cardiovas-
cular disease. J Am Coll Cardiol 2009;54:891–3.
[36] Ziegelstein RC, Thombs BD, Coyne JC, de Jonge P. Routine screening for depression
in patients with coronary heart disease never mind. J Am Coll Cardiol 2009;54:
886–90.
[37] Carney RM, Freedland KE. Treatment-resistant depression and mortality after
acute coronary syndrome. Am J Psychiatry 2009;166:410–7.
[38] Irvine J, Firestone J, Ong L, et al. A randomized controlled trial of cognitive behav-
ior therapy tailored to psychological adaptation to an implantable cardioverter
deﬁbrillator. Psychosom Med 2011;73:226–33.
[39] Pedersen SS, van den Broek KC, Sears Jr SF. Psychological intervention following
implantation of an implantable deﬁbrillator: a review and future recommenda-
tions. Pacing Clin Electrophysiol 2007;30:1546–54.
[40] Smedslund G, Ringdal GI. Meta-analysis of the effects of psychosocial interven-
tions on survival time in cancer patients. J Psychosom Res 2004;57:123–31 dis-
cussion 133–125.
[41] Coyne JC, Stefanek M, Palmer SC. Psychotherapy and survival in cancer: the con-
ﬂict between hope and evidence. Psychol Bull 2007;133:367–94.
